Table 1.

The Evidence and Value: Impact on DEcisionMaking framework

Domains	Criteria	Type	Scoring Scale High→Low	Indicators
Need for intervention	Disease severity	Absolute	5 4 3 2 1 0 Very severe→Not severe	Morbidity, Progression, Quality of life
	Size of the affected population	Absolute	5 4 3 2 1 0 Common diseases→Very rare diseases	Disease incidence
	Unmet needs	Absolute	5 4 3 2 1 0 Many unmet needs→No unmet needs	Compliance, Response rate, Nocturnal acid breakthrough, Genetic polymorphism
Comparative outcomes of intervention	Comparative effectiveness	Relative	5 4 3 2 1 0–1 -2 -3 -4 -5 Much better than the comparator→No difference→Much worse than the comparator	Reflux esophagitis healing rate, Intragastric pH
	Comparative safety	Relative		Incidence of adverse effects
	Comparative patient-perceived health	Relative		Heartburn
Type of benefit of intervention	Type of preventive benefit	Absolute	5 4 3 2 1 0 Eradication→No preventive benefit	Preventive benefit
	Type of therapeutic benefit	Absolute	5 4 3 2 1 0 Cure→No therapeutic benefit	Therapeutic benefit
Economic consequences of intervention	Comparative cost consequences—costs of intervention	Relative	5 4 3 2 1 0–1 -2 -3 -4 -5 Substantial savings/Good affordability→No change in spending→Substantial additional expenditures/Bad affordability	Drug cost
	Comparative cost consequences—other medical costs	Relative		Pharmacoeconomic research in China
	Comparative cost consequences—non-medical costs	Relative		Pharmacoeconomic research in China
Knowledge about intervention	Quality of evidence	Absolute	5 4 3 2 1 0 Highly relevant and valid→Not relevant and/or invalid	Type of evidence, Level of evidence
	Expert consensus/clinical practice guidelines	Absolute	5 4 3 2 1 0 Strong recommendation for intervention above all other alternatives→Not recommended or invalid	Recommendation